Replies to post #10624 on GeneSYS ID Inc fka GNID

[WolfWayne]

The company is offering projections to attract financing to produce the product to achieve sales, right?

Without success in the CVS pilot program, projections will decrease, finances will view the company as less attractive, and sales ultimately won't culminate.

I don't think this is going to happen, but it could.

I don't see any details outlined by the company regarding the specifics of the regional plan in brick and mortar CVS stores, do you?

I'm optimistic the biometric/safe/drug combination is lucrative. But is the retailer going to pay nearly $200?


"Imo you don't offer projections if you don't have financing, you don't have financing if you don't have sales"

[StockMedic1]

Yea Cheeky - he needs to read more - he thinks this is a consumer products company. Go back to the biotech company example and maybe the bigger picture will materialize. The BIG money has nothing to do with the safes - that just the "feel good" story the company has that those institutional firms balance the business serious medical device picture with. Its easy to use the consumer product to make its point and use of its technology because there is a lot of emotion on the consumer side dealing with drug abuse. Those big institutional lenders invest that kind of money into medical device companies - not consumer-focused retail product companies. Its more about drug diversion and securing and controlling how controlled substances are dispensed. Thats the message I get from the company and its CEO anyway.